How should we be treating our DME patients?

Article

Dr Maeve O'Doherty discusses the literature review she conducted to determine best practice in the treatment of diabetic macular oedema.

Key Points

The optimum treatment of diabetic macular oedema (DME) has still yet to be defined. While many surgeons believe in the power of the laser, others are beginning to advocate the benefits of drug therapies. The truth is, there is no one clear winner. Laser photocoagulation treatment is one of the oldest forms of treatment for DME; hence a wealth of data in support of its efficacy exists and, as such, it is still recommended as first-line treatment for DME. However, the success rates of laser therapy are far from perfect, thus a great deal of research has been conducted in the quest to find a suitable adjunct or alternative.

The search for the answer begins

"Our aim was to arm ophthalmologists with knowledge from evidence-based research that would allow them to integrate recent ophthalmic advancements into their treatment regimes," said Dr O'Doherty. "Ultimately, we wanted to provide some clear treatment guidelines based on the patient's condition and based on the scientific evidence to date," she added.

The team performed a literature review of all English language articles from Medline and Cochrane database, confining the search to randomized controlled clinical trials in humans from 1979 to 2007. Thirty-one relevant articles were returned.

Laser therapy still the mainstay

"The ETDRS was a landmark study; not only did it help us to understand the nature of the disease, but it was also the first properly conducted randomized trial to establish the benefits of laser for the treatment of DME and proliferative diabetic retinopathy," explained Dr O'Doherty.

The evidence that laser treatment preserves vision in eyes with DME is now well documented; however no definitive consensus has been reached on the optimum laser type (argon, diode, dye, krypton) or technique.5–13 Although still considered the gold standard of DME treatment, laser therapy is not without its complications. Known adverse events include foveal burn, central visual field defect, colour vision abnormalities, retinal fibrosis, and spread of laser scars.12–14 A long-term study did find that, after five years, more than 50% of patients did not experience any laser-related complications; however, 21% were found to develop either subretinal fibrosis or atrophic creep, while hard exudates as well as all other complications were found to be more common in type 2 diabetics, thus resulting in a poorer outcome.13

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Related Content
© 2025 MJH Life Sciences

All rights reserved.